Skip to main content

Table 1 Number of reports and reporting odds ratio of BRONJ stratified by gender

From: Analysis of the time-to-onset of osteonecrosis of jaw with bisphosphonate treatment using the data from a spontaneous reporting system of adverse drug events

Dosage form Drug name Case Non-case Total Reporting odds ratio (95 % CI)
Intravenous Alendronate (I.V.)   10 48 58 43.7 (22.1 − 86.4)
   Male 2 8 10 52.1 (11.1 − 245.7)
   Famale 8 40 48 41.9 (19.6 − 89.6)
  Pamidronate   223 171 394 315.0 (256.3 − 387.0)
   Male 30 35 65 181.9 (111.4 − 297.0)
   Famale 186 128 314 341.9 (271.4 − 430.8)
  Zoledronate   809 972 1,781 346.2 (308.2 − 388.8)
   Male 301 436 737 176.5 (150.9 − 206.4)
   Famale 474 514 988 271.4 (236.5 − 311.4)
Oral Alendronate (oral)   414 1,252 1,666 92.3 (81.4 − 104.5)
   Male 22 146 168 31.8 (20.3 − 49.9)
   Famale 379 1,096 1,475 93.8 (82.4 − 106.8)
  Etidronate   16 21 37 160.3 (83.5 − 307.7)
   Male 3 4 7 156.5 (35.0 − 699.9)
   Famale 13 17 30 160.6 (77.9 − 331.1)
  Minodronate   45 558 603 17.3 (12.7 − 23.5)
   Male 4 49 53 17.0 (6.1 − 47.3)
   Famale 41 483 524 18.1 (13.1 − 25.0)
  Risedronate   152 721 873 48.4 (40.3 − 58.0)
   Male 18 81 99 46.8 (28.0 − 78.2)
   Famale 131 614 745 48.3 (39.7 − 58.7)